Japan’s NDA Examination Period Shortest Since 2000
This article was originally published in PharmAsia News
The median examination period for new drug applications in Japan in 2011 was 10.1 months, 4.7 months shorter than the previous year, according to a report from the Japan Pharmaceutical Manufacturers Association’s Office of Pharmaceutical Industry Research.
You may also be interested in...
Sanofi has received formal approval from the European Commission for its insulin aspart biosimilar.
Europe's self-care industry urges the European Commission to use Rx-to-OTC switch and real world evidence to widen access to OTC medicines in the region as part of its new pharmaceutical strategy.
Procter & Gamble failed to substantiate claims that Vicks First Defence can eliminate cold symptoms completely, says UK ad regulator ASA.